Physician profile
Jitinder Singh
NPI 1194812602
$423.54
in general payments reported to CMS, 2019-2025
13 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.26 · 2021: $44.81 · 2022: $70.41 · 2023: $54.23 · 2024: $87.41 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $280.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $83.96 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $73.90 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $51.68 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $48.69 | 2022-2023 | Freestyle Libre 3 |
| Medtronic, INC. | $24.93 | 2024 | Venaseal |
| Kowa Pharmaceuticals America, INC. | $23.88 | 2021 | |
| Esperion Therapeutics, INC. | $20.93 | 2021 | |
| Boston Scientific Corporation | $19.90 | 2025 | Bulkamid - Bulkamid Urethral Bulking Pack 2ml (Ous) |
| E.R. Squibb & Sons, L.L.C. | $18.05 | 2023 | |
| Daiichi Sankyo INC. | $16.77 | 2019 | |
| Xeris Pharmaceuticals, INC. | $15.74 | 2022 | |
| Pfizer INC. | $13.62 | 2022 | |
| Amgen INC. | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jitinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.